FIELD: biotechnology.
SUBSTANCE: invention relates to a chimeric antigen receptor (CAR) polypeptide specifically binding a tumour-associated antigen (TAA), where said CAR includes a TAA-binding domain, a transmembrane domain, an intracellular signalling domain, and a costimulatory signalling region, in which the costimulatory signalling region includes a mutated form of the CD28 cytoplasmic domain. Also disclosed is an immune effector cell comprising a nucleic acid molecule encoding the above CAR polypeptide.
EFFECT: providing anti-tumour immunity in a mammalian subject with a TAA-expressing cancer.
10 cl, 13 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
| CHIMERIC ANTIGENIC RECEPTORS WITH MND-PROMOTER | 2015 |
|
RU2708311C2 |
| CHIMERIC ANTIGENIC RECEPTORS WITH MND PROMOTER | 2015 |
|
RU2799573C2 |
| METHOD OF PRODUCTION OF T-CELLS | 2015 |
|
RU2813668C2 |
| TRANSPOSASE POLYPEPTIDES AND USE THEREOF | 2016 |
|
RU2735700C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| IMPROVED METHODS FOR PRODUCING ADOPTIVE CELL THERAPY AGENTS | 2015 |
|
RU2741899C2 |
| IMPROVED COMPOSITIONS BASED ON T-CELLS | 2015 |
|
RU2719030C2 |
| CONDITIONALLY ACTIVE CHIMERIC ANTIGENIC RECEPTORS FOR MODIFIED T CELLS | 2016 |
|
RU2759957C2 |
| CAR-T-CELLS SPECIFICALLY TARGETING CD19 ANTIGEN | 2020 |
|
RU2826298C2 |
